Shannyn Henke is a partner in Goodwin’s Technology and Life Sciences group and a member of the firm’s Strategic Technology Transactions and Licensing practice. Ms. Henke represents technology, pharmaceutical, medical device and other life science companies in connection with their commercial, M&A and intellectual property transactions, including pre-clinical, clinical and commercial contracts, and complex strategic collaboration, co-development, licensing and partnering transactions. Ms. Henke also has a strong pro bono practice, providing ongoing representation to a non-profit board of directors and securing a residential placement for a special education student. She joined Goodwin in 2015.

Areas of Practice
Domaines D’Expertise





Ms. Henke's representative matters include:

  • Licensing of intellectual property assets from research institutions
  • Alnylam Pharmaceuticals in its license and collaboration agreement with PeptiDream to discover and develop peptide-siRNA conjugates for targeted delivery of RNAi therapeutics, with a potential deal value of $2.2 billion in milestones
  • Alnylam Pharmaceuticals in its collaboration with Regeneron Pharmaceuticals for new RNA interference (RNAi) therapeutics focused on ocular and central nervous system (CNS) diseases with deal value up to $1 billion
  • Moderna in its supply agreements for Moderna’s COVID-19 vaccine with governments around the world
  • Cerevance in its research collaboration with Takeda to identify novel target proteins for certain GI disorders, for a deal value of over $170 million on a per target basis
  • Century Therapeutics in its launch by Versant Ventures, Bayer and Fujifilm Cellular Dynamics Inc. (FCDI), which included a strategic partnership with FCDI
  • Wave Life Sciences, in its global strategic collaboration with Takeda for nucleic acid therapies for CNS disorders, with potential deal value of over $2 billion
  • Scholar Rock, in its strategic collaboration with Gilead Sciences, with potential deal value of over $1.5 billion
  • JMI Equity and its affiliated investment funds with respect to intellectual property issues in connection with a majority investment in Jvion, Inc., a healthcare AI company
  • KIND Snacks, in its strategic partnership with Mars Incorporated
  • Magenta Therapeutics, in various commercial and licensing transactions
  • Nimbus Therapeutics, in its strategic alliance with Celgene Corporation in immunology
  • Teva Pharmaceuticals, in its disposition of certain assets
  • Vericel Corporation, in ongoing SEC compliance and corporate governance matters
  • Imprivata in its $544 million sale to Thoma Bravo in a "going private" transaction
  • PAREXEL in its $5 billion sale to Pamplona Capital Management in a "going private" transaction
  • Citrix Systems, Inc., in its $1.8 billion spin-out of its GoTo family of products
Professional Activities

Ms. Henke is an active participant in the firm’s recruiting, training and mentoring efforts. She is a member of the Boston Bar Association.


While attending law school, Ms. Henke served as a Managing Editor of the Boston College Law School Journal of Law and Social Justice.

In The News









JD, 2015
Boston College Law School
AB, 2012
Princeton University



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique